Division of
GMP Publications, Inc.

ohn Cuspilich
Send Comments to QA/RA Editor

Food and Drug Assistance - Resources for Industry and Consumers

 

 

 
 

Condition - Disease

Links & Resources

- Add an Forum -

Acne - see Skin Care

ADD and ADHD

AIDS/HIV

Allergies

Alzheimer's

Arthritis

Asthma

Autism

Back Pain

Birth Control

Cancer - Breast

Cancer - Prostate

Cholesterol

Common Cold  |  Flu

Crohn's & Colitis

Dental Health

Diabetes

Diet & Nutrition

Ear Disorders

Epilepsy

Erectile Dysfunction

Hair Loss

Headache | Migraine

Heartburn

Heart Attacks

Hepatitis

Hemorrhoids

Kidney

Lyme Disease

Men's Health

Multiple Sclerosis

Osteoporosis

Parkinson's

SARS

SIDS

Skin Care

Sleep Disorders

Smoking

Snoring

Stress | Depression

Stroke

Vitamins

Weight Control


 
 
Hepatitis

Clinical Trials  |  Add a link  |  Regulations  |  Discussion Board  |  Ask the Nurse | Last Update January 1st. 2009  |  About FDA.COM  | Media Kit

Hepatitis Facts: Worldwide Snapshot
Basics: Hepatitis A (HAV)
Basics: Hepatitis B (HBV)
Basics: Hepatitis C (HCV)
 
Hepatitis Facts: Worldwide Snapshot

Hepatitis A Virus (HAV) Infection:
  • In 2005, there were an estimated 42,000 Hepatitis A infections.
  • Hepatitis A is the cause of 30 days of missed work and approximately $2,600 in lost wages each year.
  • Medical care alone for hepatitis A can cost $2,800 for each hospitalized case.
  • Approximately 100 Americans die each year from Hepatitis A.
  • The annual cost associated with Hepatitis A is estimated at $200 million in the U.S.
Hepatitis B Virus (HBV) Infection:
  • HBV is 100 times more infectious than HIV, the virus that can cause AIDS.
  • Hepatitis B vaccine can provide immunity in over 95% of young healthy adults.
  • An estimated 350 million people are infected globally with HBV.
  • Approximately 1 million die each year from complications from HBV.
  • 70% of new cases occur among people between the ages of 15-39.
  • Every year 5,000 Americans die from cirrhosis and 1,000 from liver cancer due to HBV infections.
  • 22,000 pregnant women in the U.S. are infected with HBV and can transmit it to their newborns.
  • HBV can live on a dry surface for at least 7 days.
Hepatitis C Virus (HCV) Infection:
  • 3% of the world's population is infected with HCV, or approximately 170 million people. 90% of HCV patients who are in need of treatment today cannot afford it.
  • 80% of affected people can become chronically infected and risk serious long-term clinical disease including cirrhosis and liver cancer.
  • 8 countries – Bolivia, Burundi, Cameroon, Egypt, Guinea, Mongolia, Rwanda, and Tanzania – have an HCV prevalence above 10%.
  • 7 countries/areas – Gabon, Libya, Papua New Guinea, Suriname, Vietnam, Zaire, and the United Nations Relief and Works Agency for Palestine Refugees in the Near East – have an HCV prevalence between 5 and 10%.
  • In developing countries, the primary sources of HCV infection include transfusion of blood or blood products from unscreened donors; transfusion of blood products that have not undergone viral inactivation; parenteral exposure to blood through the use of contaminated or adequately sterilized instruments and needles used in medical and dental procedures; the use of unsterilized objects for rituals (e.g. circumcision, scarification), traditional medicine (e.g. blood-letting) or other activities that break the skin (e.g. tattooing, ear or body-piercing); and intravenous drug use. Household or sexual contacts of HCV-infected persons are marginally at risk.
  • In developed countries, persons at risk of HCV infection include recipients of previously unscreened blood, blood products, and organs; intravenous drug users; individuals undergoing chronic hemodialysis; health care workers with percutaneous exposure from contaminated needles or sharps; persons who participate in high-risk sexual practices; and persons undergoing medical or dental procedures with inadequately sterilized instruments. Sexual and household transmission are uncommon.

     
Basics: Hepatitis A (HAV)

What is Hepatitis A ?
Hepatitis A is one of many hepatitis viruses causing inflammation of the liver.

Who Is At Risk?
Hepatitis A can affect anyone. In the U. S., hepatitis A can occur in situations ranging from isolated cases of disease to widespread epidemics. Hepatitis A is one of the most frequently reported vaccine-preventable diseases in the U. S. Some of the higher-risk groups are: travelers to countries with high rates of hepatitis A, men who have sex with men, injecting-drug users, people with clotting-factor disorders, people with chronic liver disease, and children living in communities with high rates of disease.


Symptoms
Children with hepatitis A usually have no symptoms. Adults may become quite ill suddenly, experiencing jaundice, fatigue, nausea, vomiting, abdominal pain, dark urine/light stools, and fever. The incubation period averages 30 days. However, an infected individual can transmit the virus to others as early as two weeks before symptoms appear. Symptoms will disappear over a 6 -12-month period until complete recovery occurs.

Diagnosis
Your doctor can't single out Hepatitis A from other types of viral hepatitis based upon your physical symptoms alone. The only way to diagnose HAV is to do a blood test seeking to find IgM antibodies. In most people, these antibodies become detectable 5-10 days before the onset of symptoms and can persist for up to 6 months after infection.

How Does it Spread?
Hepatitis A is most often spread from person to person through situations such as these:
  • Food preparers who are infected can pass the virus on if they do not wash their hands with soap and water after having a bowel movement, especially when they prepare uncooked foods.
  • Fecal contamination of food and water.
  • Anal/oral contact, by putting something in the mouth that had been contaminated with infected feces.
  • Diaper changing tables, if not cleaned properly or changed after each use, may facilitate the spread of HAV.
  • Fecal residue may remain on the hands of people changing soiled diapers.
  • Eating raw or partially cooked shellfish contaminated with HAV.
Treatment
No specific treatment is necessary for hepatitis A. Disease

Outcome
Hepatitis A will clear up on its own in a few weeks or months with no serious after effects. Once recovered, an individual is then immune for life to HAV through the presence of the IgG antibody . About 1 in 100 HAV sufferers may experience a sudden and severe (i.e., "fulminant") infection.

Preventing HAV

Infection HAV infection is preventable! Here's how you do it:
  • Get an immune globulin (IG) shot. An IG shot can provide temporary immunity to the virus for 2 to 3 months when given prior to exposure to HAV or within 2 weeks after exposure.
  • Ask for the HAV vaccine. The HAV vaccine, made from inactive hepatitis A virus (synthetic), is highly effective in preventing the hepatitis A infection. However, its safety when given during pregnancy has not been determined. Check with your doctor to determine how many shots you need. The vaccine provides protection for about four weeks after the first injection; a second injection protects you longer, possibly up to 20 years.
Who should have the HAV vaccine?
  • Users of illegal drugs.
  • Individuals who have chronic liver disease or blood clotting disorders (e.g., hemophilia).
  • Those who have close physical contact with people who live in areas with poor sanitary conditions.
  • Those who travel or work in developing countries. This includes all countries except northern and western Europe, Japan, Australia, New Zealand, and North America except Mexico.
  • Men who have sex with other men.
  • Children in populations that have repeated epidemics of hepatitis A (e.g., Alaska natives, American Indians, and certain closed religious communities).
  • People who have chronic lever disease.
     

Basics: Hepatitis B (HBV)


What is Hepatitis B?
Hepatitis B is an inflammatory liver disease caused by the hepatitis B virus (HBV) that results in liver cell damage. This damage can lead to scarring of the liver (cirrhosis) and increased risk of liver cancer in some people. About 80,000 Americans were newly infected with HBV in 1999.

Who Is At Risk?
One out of every 20 people in the U. S. will become infected with HBV sometime during their lives. Your risk is higher if you:
  • Have sex with someone infected with HBV.
  • Have sex with more than one partner.
  • Are a man and have sex with a man.
  • Live in the same house with someone who has chronic HBV infection.
  • Have a job that involves contact with human blood.
  • Inject illegal substances/drugs. Have hemophilia.
  • Travel to areas where HBV is common (this includes all countries except northern and western Europe, Japan, Australia, New Zealand, and North America except Mexico).
Symptoms
Many people with newly acquired hepatitis B have no symptoms at all, or they may be very mild and flu-like – loss of appetite, nausea, fatigue, muscle or joint aches, mild fever, and possibly jaundice (yellowish tinge to the skin). The only way to know if you are currently infected with HBV – or if you still carry the virus – is to ask your doctor to do a specific blood test for hepatitis B (it may not be included in a routine blood test). The test may not show positive during the incubation period (45-180 days).

Diagnosis
There are three standard blood tests for HBV:
  • HBsAG (hepatitis B surface antigen):
    When this test is positive or reactive, you are infected with HBV and can pass it on to others.
  • Anti-HBc (antibody to hepatitis B core antigen):
    When you test positive, it means you are currently infected with HBV or have been infected at some point in the past.
  • Anti-HBs (antibody to HbsAg):
    When this test is positive, it means that you are immune to hepatitis B either as a result of having had the disease or from having been given the vaccine.
How Does It Spread?
HBV is found in blood, seminal fluid, and vaginal secretions. The risk of transmission is increased in these situations:
  • Sexual contact with an infected person.
  • Living in the same household with an infected individual.
  • Contact with infected blood or seminal fluid and contaminated needles, including tattoo/body piercing instruments.
  • HBV-infected mother to her newborn at time of delivery (prenatal blood tests for HBV should always be done if there is a suspicion of HBV).
Treating HBV
There are two medications to treat chronic HBV – Interferon (IFN) and Lamivudine. Less than 50% of patients with chronic HBV are candidates for interferon therapy. Initially, 40% of HBV patients who are treated with IFN will respond. However, some will relapse when the treatment is stopped. Overall, about 35% of the eligible patients will benefit. IFN treatments may have a number of side effects, including flu-like symptoms, headache, nausea, vomiting, loss of appetite, depression, diarrhea, fatigue, and thinning hair. Interferon may lower the production of white blood cells and platelets by depressing the bone marrow. Thus, blood tests are needed to monitor blood cells, platelets, and liver enzymes. The response to oral Lamivudine, given for at least one year, may be somewhat lower. In addition, those who are chronically infected with HBV should be vaccinated against hepatitis A. There is no treatment for acute Hepatitis B.

Disease Outcome
- Either you develop immunity to HBV . . . 95% of adults infected develop antibodies and recover spontaneously within six months. Upon recovery, they develop immunity to the virus and they are not infectious to others. Blood tests will always test positive for the HBV antibody. Blood banks will not accept donations of blood from HBV-immune people.
- OR you become chronically infected. About 5% of the time, the virus does not clear the body within six months. If so, a person is considered a carrier – or chronically infected. Chronically infected people may or may not show outward signs or symptoms. The HBV virus remains in blood and body fluids, and can infect others.


Preventing HBV Infection - Things you can do:
  • Practice safe sex (use latex condoms).
  • Don't share anything that could have an infected person's blood on it, i.e. toothbrushes, razors, nail clippers, body piercing instruments.
  • Don't share drug needles, cocaine straws or any drug paraphernalia.
  • Cover all sores and rashes and do not touch them.
  • Clean up any blood spills with a 10% solution of household bleach. Infected persons should not pre-chew food for babies.
  • If exposed to hepatitis B, get an HBIG (hepatitis B immune globulin) injection within 14 days following exposure.
Get an HBV vaccination.
Here's who should be vaccinated without fail:
  • All individuals living in the same household with a chronically infected individual.
  • All newborns and children up to the age of 19.
  • Those who are in positions where they are exposed to blood at work, through drug use, or who have multiple sex partners.
  • Individuals with hepatitis C and other chronic liver diseases.
Vaccination provides protection for more than 15 years, and possibly a lifetime. HBV booster shots are not recommended.

Newborn Vaccination
All newborns should get three vaccination doses of the HBV vaccine ­ the first within 12 hours of birth, the second at 1-2 months, and the third at 6 months. In addition, babies born to infected mothers should receive a shot called H-BIG within 12 hours of delivery. Without the above intervention, 90% of babies born to infected mothers will become chronically infected, reducing their life expectancies. A few months after the last dose is given, the doctor will test to see if the baby is making HBV antibodies. If so, the baby will be safe from hepatitis B for life. HBV-infected mothers may nurse their babies.

Basics: Hepatitis C (HCV)

What Is Hepatitis C ?
Hepatitis C virus (HCV) causes inflammation of the liver. A national U. S. survey found that 1.8 percent of Americans – about 3.9 million – have been infected with HCV, of whom most ­ about 2.7 million – are chronically infected with HCV, with many showing no signs or symptoms. The good news is that, in 1995, a reliable antibody test for HCV was finally implemented nationwide. About 41,000 new cases occurred in 1998 with 15-25% recovering spontaneously. Hepatitis C is a slow-progressing disease that may take 10-40 years to cause serious liver damage in some people.


Who Is At Risk?

Since about four million Americans are infected with HCV and most don't know it, you should have a blood test for hepatitis C ­ whether you feel sick or not. About one in ten people infected with HCV have had no identifiable exposure to HCV. That said, here are several obvious risk factors:
  • Intravenous (IV) drug users – even IV use in the distant past.
  • Those with multiple sex partners or sex with partners who have other sexually transmitted diseases.
  • Those with tattoos or body piercing done with unsterile instruments. Anyone who has had a blood transfusion prior to 1992 or clotting factors produced before 1987.
  • Hemodialysis (diabetes) patients.
  • The potential for transmission from an HCV-infected mother to her newborn appears to be about 5%.
How Does it Spread?
  • Injection drug use is the primary risk for HCV infection. Injection drug use accounts for about 60% of all new cases of hepatitis C and is a major risk factor for infection with hepatitis B virus. Among frequent drug users, 50-80% are infected by HCV within the first 12 months of beginning injecting.
  • Straws shared in snorting drugs are also a potential source of infection of HCV. The hepatitis C virus is found mainly in blood.
  • HCV is not spread through kissing or casual contact.
  • In relationships where there is one steady partner, sexual transmission is exceedingly unusual, less than 3% over decades in sexually active couples.  Transmission from HCV RNA negative individuals has never been reported.  Sexual transmission may be more common among those with multiple sex partners or where there is a history of sexually transmitted disease but this remains controversial and unconfirmed.
  • HCV may be transmitted by using razors, needles, toothbrushes, nail files, a barber's scissors, tattooing equipment, body piercing or acupuncture needles if these items are contaminated by blood of an infected person.
  • Healthcare workers have a 2% risk of acquiring HCV after a needle stick contaminated with HCV-positive blood.
  • There is no evidence indicating that HCV is transmitted through breast milk.
  • The current transmission rate through blood transfusions is estimated at less than 1 per 1,000,000 units transfused.
Symptoms
Most people who are infected with the HCV do not have symptoms and are leading normal lives. If symptoms are present, they may be very mild and flu-like – nausea, fatigue, loss of appetite, fever, headaches, and abdominal pain. Most people do not have jaundice although jaundice can sometimes occur along with dark urine.

The incubation period varies from 2-26 weeks. Liver enzyme tests may range from being elevated to being normal for weeks to as long as a year. The virus is in the blood and may be causing liver cell damage, and the infected person can transmit the disease to others.


Diagnosis
Test for HCV antibodies: HCV infection can be determined by a simple and specific blood test that detects antibodies against HCV. The current enzyme immunoassay test (EIA) that detects anti-HCV has a sensitivity of about 95% in chronic HCV. HCV infection may be identified by anti-HCV testing in approximately 80% of people as early as five weeks after exposure. This test is not a part of a routine physical examination, and people must ask their doctor for a hepatitis C antibody test. (Note: The antibody itself does not provide immunity, and the test does not distinguish between acute or chronic infection.) If the initial test is positive, it test should be repeated to confirm the diagnosis (and exclude possible laboratory error). If the initial test is negative, but the infection could have occurred within the last six months and HCV is suspected, antibody levels may not be high enough yet to be detectable (antibodies may not be present in the first 4 weeks of infection in about 30% of patients) or you may lack immune response. Under these circumstances, ask you doctor about repeating the test and about alternative test methods.

Test liver enzyme levels: If you may already have chronic infection, your doctor will test the levels of two liver enzymes. These are alanine aminotransferase (ALT) and aspartate aminotrasferase (AST). Both are released when liver cells are injured or die. Elevated ALT and AST levels may appear and disappear throughout the course of the HCV infection. If the liver enzyme levels are normal with chronic HCV, they should be re-checked several times over a 6 - 12 month period. If the liver enzyme levels remain normal, your doctor may check them less frequently, such as once a year.


Treating HCV
  • There are three types of interferon, plus a combination of interferon and ribavirin, used to treat hepatitis C. Blood tests and liver biopsy findings may determine the need for treatment.
  • Interferon must be given by injection, and may have a number of side effects, including flu-like symptoms – headaches, fever, fatigue, loss of appetite, nausea, vomiting, and thinning of hair.
  • Ribavirin, given by mouth, can have additional side effects including depression, severe anemia and especially birth defects. Women or the male partners of women, who are pregnant or who are planning pregnancy, should not take ribavirin. Pregnancy should not be attempted until six months after treatment is ended. Ribavirin may also interfere with the production of red blood cells and platelets by depressing bone marrow. Patients should be monitored frequently.
  • While 50-60% of patients respond to treatment initially, sustained response occurs in up to 40%.
  • Treatment of children with HCV is under investigation.
  • Researchers are re-examining when treatment should begin, for how long it should continue, and its effectiveness.
  • Many pharmaceutical companies and NIH are conducting research to find more effective treatments and cures.
  • Currently, almost 1/2 of all liver transplants in the US are performed for end-stage hepatitis C. However, re-infection of the transplanted liver by the virus usually occurs and may require a second transplant.
  • Try to maintain as normal a life as possible, eating a well-balanced diet, exercising and keeping a positive attitude. Avoid depressing or overwhelming tasks and learn how to pace yourself. Rest when you feel tired. Plan physically exhausting tasks in the morning when your energy level is at its peak.
Disease Outcomes
Between 20- 30 percent of HCV sufferers are able to become virus-free with proper treatment. Between 70 ­ 80% of the HVC infections reported each year become classified as chronic. Chronic HCV refers to infections that do not clear up within 6 months after the acute infection. Within the chronically infected group, about 20% go on to develop cirrhosis (scarring of the liver). Of this group, 25% may develop liver failure, even though this may take 30-40 years. Cirrhosis slows the blood flow through the liver and causes increased pressure in the vein that carries blood from the stomach and the intestines to the liver. As a result, varicose veins (e.g., "varices") may develop in the stomach and esophagus. Without warning these large veins can break causing a person to vomit blood or have black, tarry stools. An estimated 8,000-10,000 deaths occur each year resulting from the complications of HCV.

Preventing HCV Infection
  • There is NO vaccine to prevent HCV.Vaccines for Hepatitis A and B do not provide immunity against hepatitis C. There are various genotypes of HCV and the virus undergoes mutations making it difficult to develop a vaccine.
  • Avoid handling anything that may have the blood of an infected person on it, such as razors, scissors, toothbrushes, nail clippers or files, tampons or sanitary napkins, etc. Detergent and a 10% solution of household bleach is believed to kill the virus.
  • Don' t share drug needles, cocaine straws or any drug paraphernalia.
  • Practice safe sex (use latex condoms).
  • Notify your physician and dentist that you have hepatitis .
  • Get vaccinated against hepatitis A and B.
  • Those infected with hepatitis C should not drink alcohol, as it accelerates the liver damage.
 

 

Reference Links - Add a link

Clinical Trials - Add a clinical trial

 top
1
Recruiting
Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
Conditions:
Hepatitis B, Chronic;   Hepatitis C, Chronic 
Intervention:
Drug: Peginterferon Alfa-2a plus Ribavirin 
 
 

 
2
Recruiting
The Hepatitis B Vaccine Booster Response Among the Youth Who Had Completed Neonatal Hepatitis B Vaccines
Condition:
Hepatitis B 
Intervention:
Biological: hepatitis B vaccine 
 
 

 
3
Recruiting
HIV and Hepatitis Care Coordination in Methadone Treatment
Conditions:
Hepatitis, Viral, Human;   HIV Infections 
Interventions:
Behavioral: HIV and Hepatitis Testing, Education, and Counseling (TEC);   Behavioral: HIV and Hepatitis Care Coordination (HCC) 
 
 

 
4
Recruiting
Truvada Versus Truvada Plus HBIG in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant
Condition:
Chronic Hepatitis B 
Interventions:
Drug: emtricitabine/tenofovir disoproxil fumarate plus Hepatitis B Immunoglobulin;   Drug: emtricitabine/tenofovir disoproxil fumarate 
 
 

 
 
6
Recruiting
Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
Conditions:
Chronic Hepatitis B;   Chronic Hepatitis D 
Intervention:
Drug: pegylated IFN alfa-2b plus ribavirin 
 
 

 
7
Recruiting
Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy
Conditions:
Hepatitis C;   Hepatitis B 
Intervention:
Drug: Pegasys; Copegus. 
 
 

 
8
Not yet recruiting
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
Conditions:
Chronic Hepatitis B Liver Disease;   Orthostotic Liver Transplant 
Intervention:
Biological: Hepatitis B immune globulin (Human) 
 
 

 
9
Recruiting
Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B
Condition:
Chronic Hepatitis B 
Interventions:
Drug: Pegasys plus Entecavir;   Drug: Entecavir 
 
 

 
10
Not yet recruiting
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Conditions:
Hepatitis B;   Human Immunodeficiency Virus;   Hepatitis C, Chronic 
Interventions:
Drug: maraviroc;   Drug: etravirine 
 
 

 
11
Recruiting
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
Conditions:
Chronic Hepatitis;   Hepatitis B 
Interventions:
Drug: Clevudine;   Drug: Adefovir 
 
 

 
12
Recruiting
Pretreatment With Ribavirin Before Peginterferon and Ribavirin Therapy for Chronic Hepatitis C
Condition:
Hepatitis C, Chronic 
Interventions:
Procedure: Liver Biopsy;   Drug: Peginterferon & Ribavirin for Hepatitis C;   Drug: Pre-treatment Ribavirin 
 
 

 
13
Recruiting
HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients
Condition:
Chronic Hepatitis C 
Interventions:
Drug: Oral HDV-Interferon + ribavarin;   Drug: Injectable HDV-Interferon + ribavarin 
 
 

 
14
Recruiting
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B
Conditions:
Chronic Hepatitis B e Antigen Positive;   Chronic Hepatitis B e Antigen Negative 
Intervention:
Drug: Tenofovir/ & Emtricitabine 
 
 

 
15
Recruiting
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis
Conditions:
Hepatitis C;   Hepatitis B;   Autoimmune Hepatitis;   Liver Cirrhosis, Biliary;   Cholangitis, Sclerosing 
Intervention:
 
 
 

 
16
Recruiting
An Extension to Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
Condition:
Chronic Hepatitis B 
Intervention:
Drug: telbivudine 
 
 

 
17
Recruiting
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
Conditions:
Chronic Hepatitis;   Hepatitis B 
Interventions:
Drug: Clevudine;   Drug: Adefovir 
 
 

 
18
Recruiting
Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-Treated With Vasopressin
Conditions:
Chronic Hepatitis C;   Chronic Hepatitis B;   Biopsy;   Hemodialysis 
Interventions:
Procedure: Percutaneous liver biopsy;   Procedure: Percutaneous liver biopsy 
 
 

 
19
Recruiting
 

 
20
Recruiting
Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator
Condition:
Hepatitis B 
Interventions:
Biological: Resiquimod gel;   Biological: Resiquimod gel;   Biological: Resiquimod gel 
 
 

 
21
Recruiting
 

 
22
Not yet recruiting
Randomized Placebo-Controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis
Conditions:
Acute Hepatitis A;   Acute Hepatitis B;   Acute Hepatitis C;   Acute Hepatitis E;   Acute EBV Hepatitis;   Acute CMV Hepatitis 
Interventions:
Dietary Supplement: Silymarin;   Dietary Supplement: Silymarin;   Other: Lactose monohydrate 
 
 

 
23
Recruiting
Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
Conditions:
Hepatitis C;   HIV Infections 
Interventions:
Drug: Peginterferon alpha-2b;   Drug: Ribavirin 
 
 

 
24
Recruiting
Pegylated Interferon to Treat Chronic Hepatitis D
Condition:
Hepatitis D 
Intervention:
Drug: Peginterferon Alpha-2a 
 
 

 
25
Recruiting
Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection
Condition:
Hepatitis C 
Interventions:
Dietary Supplement: Omega-3 Fatty Acids;   Drug: Placebo comparator 
 
 

 
26
Recruiting
SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study
Condition:
Hepatitis C 
Intervention:
Other: Sho-saiko-to 
 
 

 
27
Recruiting
Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver Transplantation
Conditions:
Hepatitis C Virus Infection;   Liver Transplantation 
Intervention:
Procedure: Gradual immunosuppression drug withdrawal. 
 
 

 
 
29
Recruiting
Hepatitis C Treatment and Atherosclerosis
Conditions:
Chronic Hepatitis C;   Atherosclerosis 
Intervention:
 
 
 

 
30
Recruiting
Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)
Conditions:
Hepatitis C;   HIV Infections 
Intervention:
Procedure: venous blood puncture 
 
 

 
 
32
Recruiting
Transplant-Related Accelerated Progression of Hepatitis C
Conditions:
Hepatitis C;   Cirrhosis 
Intervention:
 
 
 

 
33
Not yet recruiting
Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine
Condition:
Hepatitis B 
Interventions:
Biological: Engerix-B™;   Biological: Fendrix™;   Biological: GSK Biologicals' Hepatitis B vaccines (GSK223192A);   Biological: HBsAg (Booster injection) 
 
 

 
34
Recruiting
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
Condition:
Chronic Hepatitis C 
Interventions:
Drug: Peginterferon;   Drug: Ribavirin;   Drug: SAMe for Chronic Liver Disease 
 
 

 
35
Recruiting
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
Conditions:
Hepatitis C;   Vasculitis 
Intervention:
Drug: Rituximab 
 
 

 
36
Recruiting
Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C
Condition:
Hepatitis C 
Interventions:
Drug: Infliximab;   Other: Placebo 
 
 

 
37
Recruiting
FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy
Conditions:
Cirrhosis;   Hepatitis B;   Hepatitis C 
Intervention:
Device: FibroScan 
 
 

 
38
Recruiting
Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-Infected Patients Non Responding to Primary Immunization (B-BOOST)
Conditions:
Hepatitis B;   HIV Infection 
Interventions:
Biological: GenHevac-B;   Biological: GenHevac-B 
 
 

 
39
Recruiting
Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients
Condition:
Chronic Hepatitis B 
Intervention:
Drug: Prednisone Priming 
 
 

 
40
Not yet recruiting
 

 
41
Recruiting
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
Condition:
Chronic Hepatitis C 
Interventions:
Drug: Peginterferon;   Drug: Ribavirin 
 
 

 
42
Recruiting
A Study Evaluating 24-Week Telaprevir-Based Treatment, or Extended Treatment to 48 Weeks, in Chronic Hepatitis C Patients Who Achieve a Rapid Viral Response
Condition:
Hepatitis C 
Interventions:
Drug: telaprevir;   Drug: ribavirin;   Biological: peginterferon alfa-2a 
 
 

 
43
Recruiting
Hepatitis B and HIV Co-Infection in Uganda
Conditions:
Hepatitis B;   HIV 
Intervention:
 
 
 

 
44
Not yet recruiting
A Phase II Study to Determine the Safety and Efficacy of Interferon-Gamma in Patients With Chronic Hepatitis B
Condition:
Hepatitis B 
Interventions:
Drug: IFN-γ 1b (Actimmune);   Drug: Adefovir dipivoxil;   Drug: IFN-γ 1b and Adefovir dipivoxil combination 
 
 

 
 
46
Recruiting
Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection
Condition:
Recurrent Hepatitis C 
Interventions:
Drug: Everolimus;   Drug: standard treatment 
 
 

 
47
Recruiting
Prevention of Depression in HIV/HCV co-Infected Substance Abuse Patients
Conditions:
Hepatitis C;   Depressive Disorder, Major;   Depressive Disorder;   Depression;   HIV Infections 
Interventions:
Behavioral: Hepatitis C educational support groups;   Behavioral: Cognitive Behavioral Therapy skills based group sessions 
 
 

 
48
Not yet recruiting
A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis B
Conditions:
Hepatitis B, Chronic;   Liver Diseases;   Virus Diseases;   Hepatitis;   Diffuse Hepatic Disease 
Intervention:
Device: Liquid Acupuncture (Herb Acupoint Injection) 
 
 

 
49
Not yet recruiting
Hepatitis B Vaccine Incentive Trial in Injecting Drug Users (IDUs)
Condition:
Hepatitis B 
Intervention:
Other: Incentive condition 
 
 

 
50
Recruiting
 
51
Recruiting
The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma
Conditions:
Hepatitis B;   Hepatocellular Carcinoma 
Intervention:
Procedure: radiofrequency ablation 
 
 

 
52
Not yet recruiting
Response to Hepatitis B Vaccine in Celiac Disease Patients
Condition:
Celiac Disease 
Interventions:
Biological: hepatitis B vaccine (EngerixB);   Biological: hepatitis B vaccine (EngerixB) 
 
 

 
53
Recruiting
Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels
Condition:
Chronic Hepatitis C 
Intervention:
Drug: Peg-Interferon alpha2a plus Ribavirin 
 
 

 
54
Recruiting
Comparison of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4
Condition:
Hepatitis C 
Interventions:
Drug: Pegylated interferon alpha 2a;   Drug: Ribavirin;   Drug: Pegylated interferon alpha 2 b plus ribavirin 
 
 

 
55
Recruiting
Pioglitazone in Hepatitis C
Condition:
Chronic Hepatitis C 
Intervention:
Drug: Pioglitazone 
 
 

 
56
Recruiting
Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-Infected Patients
Condition:
Hepatitis C 
Intervention:
Drug: pegylated interferon 
 
 

 
57
Recruiting
Immune Response to Hepatitis C Virus
Condition:
Hepatitis C 
Intervention:
 
 
 

 
58
Recruiting
 

 
59
Recruiting
Management of Hepatitis C in HIV-Infected and Uninfected IDUs
Conditions:
Hepatitis C Virus;   HIV Infections 
Intervention:
Drug: Peginterferon/Ribavirin 
 
 

 
60
Recruiting
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
Condition:
Hepatitis C, Chronic 
Intervention:
Drug: Irbesartan 
 
 

 
61
Recruiting
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
Conditions:
Measles;   Mumps;   Rubella;   Hepatitis A 
Interventions:
Biological: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella;   Biological: Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine;   Biological: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella 
 
 

 
62
Recruiting
Increasing Hepatitis B Screening Among Korean Church Attendees
Condition:
Hepatitis B 
Interventions:
Behavioral: Educational Small Group Session;   Behavioral: Educational small group session 
 
 

 
63
Recruiting
Immune Response to Hepatitis C Virus
Conditions:
Hepatitis C;   HIV Infections 
Intervention:
 
 
 

 
64
Recruiting
Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan
Condition:
Chronic Hepatitis C 
Intervention:
Drug: Pegylated interferon alfa and ribavirin 
 
 

 
65
Recruiting
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Dialysis Patients With Chronic Hepatitis C
Condition:
Chronic Hepatitis C 
Interventions:
Drug: Pegylated interferon alfa-2a plus low dose ribavirin;   Drug: Pegylated interferon alfa 
 
 

 
66
Recruiting
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Conditions:
Chronic Hepatitis C;   Neoplasms 
Interventions:
Drug: pegylated interferon alpha 2a and plus ribavirin;   Drug: pegylated interferon alpha 2a and plus ribavirin 
 
 

 
67
Recruiting
Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
Conditions:
Hepatitis C, Chronic;   Hepacivirus 
Interventions:
Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908) 
 
 

 
68
Recruiting
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
Conditions:
Liver Transplant;   Hepatitis C 
Intervention:
Drug: Cyclosporine microemulsion and tacrolimus 
 
 

 
69
Recruiting
Trial of Pegasys® in Patients With Chronic Hepatitis C
Condition:
Chronic Hepatitis C 
Interventions:
Drug: Pegasys®;   Drug: Pegasys® 
 
 

 
70
Recruiting
Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin
Conditions:
Chronic Hepatitis C;   Hemodialysis 
Intervention:
Drug: Pegylated interferon alfa-2a and ribavirin 
 
 

 
71
Recruiting
Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients
Conditions:
Chronic Hepatitis B;   HIV Infections 
Interventions:
Drug: pegylated interferon alfa-2a;   Drug: tenofovir DF / emtricitabine combination therapy;   Drug: pegIFN / TDF / FTC combination therapy 
 
 

 
72
Recruiting
Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C
Conditions:
Chronic Hepatitis C;   Genotype 
Interventions:
Drug: pegylated interferon alpha 2a and plus ribavirin;   Drug: Pegylated interferon alfa-2a and ribavirin;   Drug: pegylated interferon alpha 2a and ribavirin;   Drug: pegylated interferon alpha 2a and ribavirin 
 
 

 
73
Recruiting
Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Conditions:
Hepatitis B;   Liver Transplantation 
Intervention:
Biological: HepaGam B 
 
 

 
74
Not yet recruiting
Rosuvastatin for Hepatitis C
Condition:
Hepatitis C 
Intervention:
Drug: rosuvastatin 
 
 

 
75
Recruiting
Genetics of Hepatitis C Virus Infection
Conditions:
Hepatitis C;   Liver Disease 
Intervention:
 
 
 

 
76
Recruiting
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
Condition:
Hepatitis C 
Interventions:
Drug: PEG-Intron; Rebetol;   Other: No treatment, Control 
 
 

 
77
Recruiting
Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication
Conditions:
Hepatocellular Carcinoma;   Hepatitis B Virus 
Intervention:
 
 
 

 
78
Recruiting
A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C
Conditions:
Hepatitis C;   Hepatitis C Virus 
Interventions:
Drug: Fluvastatin;   Drug: Peginterferon alfa2a;   Drug: ribavirin 
 
 

 
79
Recruiting
A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection
Condition:
Chronic Hepatitis B 
Intervention:
Drug: Tenofovir disoproxil fumarate 
 
 

 
80
Not yet recruiting
Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis C
Conditions:
Obesity;   Insulin Resistance;   Metabolic Syndrome;   Hepatitis C 
Intervention:
Other: Lifestyle intervention 
 
 

 
81
Recruiting
Acute Viral Hepatitis and Diabetes Mellitus
Conditions:
Acute Viral Hepatitis;   Diabetes Mellitus 
Intervention:
 
 
 

 
82
Recruiting
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
Conditions:
Liver Transplantation;   Hepatitis B 
Intervention:
Biological: HBV vaccine booster 
 
 

 
83
Recruiting
 

 
84
Recruiting
Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus
Conditions:
Fatty Liver;   Hepatitis C 
Intervention:
Drug: Xenical vs Placebo, behavior modification, Pegasys, Copegus 
 
 

 
85
Recruiting
 

 
86
Not yet recruiting
A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
Condition:
Chronic Hepatitis C 
Interventions:
Drug: CF 102;   Drug: Placebo 
 
 

 
87
Recruiting
Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Conditions:
Hepatitis C;   Hemophilia 
Interventions:
Drug: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin);   Drug: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) 
 
 

 
88
Recruiting
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
Conditions:
Hepatitis C;   Hepatitis C, Chronic 
Interventions:
Procedure: Continuous maintenance immunosuppressive therapy;   Procedure: Immunosuppression withdrawal;   Procedure: Liver transplant 
 
 

 
89
Recruiting
Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection
Conditions:
Hepatitis C;   Thalassemia 
Intervention:
Drug: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) 
 
 

 
90
Recruiting
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Condition:
Chronic Hepatitis C 
Interventions:
Drug: Pegylated interferon alfa-2a + ribavirin;   Drug: Pegylated interferon alfa-2a + ribavirin;   Drug: Pegylated interferon alfa-2a + ribavirin;   Drug: Pegylated interferon alfa-2a + ribavirin;   Drug: Pegylated interferon alfa-2a + ribavirin 
 
 

 
91
Recruiting
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Patients With/Without Substitution Therapy (Study P05255)
Condition:
Hepatitis C, Chronic 
Interventions:
Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908) 
 
 

 
92
Recruiting
 

 
93
Recruiting
Trial for Hepatocellular Carcinoma Related Viral Hepatitis Adjuvant Treatment
Conditions:
Carcinoma, Hepatocellular;   Hepatitis, Viral, Human 
Intervention:
Drug: 131 I-lipiodol 
 
 

 
94
Recruiting
Innate Immunity in HIV Positive Patients co-Infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)
Conditions:
HIV-Hepatitis co-Infection;   HIV Infections 
Intervention:
 
 
 

 
95
Recruiting
Hepatitis C Virus and the Humoral Immune System
Condition:
Hepatitis C Virus 
Intervention:
 
 
 

 
96
Recruiting
Hepatitis C Treatment of Inmates
Condition:
Chronic Hepatitis C 
Intervention:
Procedure: Fast initiation procedure 
 
 

 
97
Recruiting
Genetic Susceptibility or Resistance to Hepatitis B Virus in the Chinese Population
Conditions:
Liver Cancer;   Precancerous/Nonmalignant Condition 
Interventions:
Procedure: gene expression analysis;   Procedure: gene expression profiling;   Procedure: genetic linkage analysis;   Procedure: laboratory biomarker analysis;   Procedure: polymorphism analysis;   Procedure: questionnaire administration 
 
 

 
98
Not yet recruiting
Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)
Condition:
Chronic Hepatitis B 
Interventions:
Drug: telbivudine;   Drug: tenofovir disproxil fumarate;   Drug: telbivudine plus tenofovir disproxil fumarate 
 
 

 
99
Recruiting
Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis
Conditions:
Primary Biliary Cirrhosis;   Autoimmune Hepatitis 
Intervention:
Drug: Budesonide 
 
 

 
100
Not yet recruiting
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (Study P05484)
Conditions:
Hepatitis C;   Hepatitis C, Chronic 
Interventions:
Biological: Peginterferon alfa-2b;   Drug: Ribavirin 
 
 
101
Recruiting
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
Condition:
Hepatitis C 
Intervention:
Drug: MP-424 
 
 

 
102
Recruiting
Overcoming Psychiatric Barriers to the Treatment of Hepatitis C
Conditions:
Hepatitis C;   Substance Use Disorders;   Mental Disorder 
Intervention:
Behavioral: psychosocial intervention 
 
 

 
103
Recruiting
Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM1)
Condition:
Hepatitis C, Chronic 
Interventions:
Drug: Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin;   Drug: Combination of (a) pegylated interferon alfa-2b and (b) ribavirin 
 
 

 
104
Recruiting
Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus
Conditions:
Hepatitis C Virus;   HIV Infections 
Intervention:
Drug: bavituximab 
 
 

 
105
Recruiting
Effect of Polymorphisms in the IL-1 Gene Complex on the Development of Chronic Hepatitis and Hepatocellular Carcinoma
Conditions:
Hepatitis B;   Carcinoma, Hepatocellular;   Polymorphism, Genetic 
Intervention:
 
 
 

 
106
Recruiting
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
Condition:
Hepatitis B 
Interventions:
Drug: tenofovir disoproxil fumarate;   Drug: placebo 
 
 

 
107
Recruiting
Viral & Host Factors Associated With Hepatitis B Virus-Related Hepatocellular Carcinoma
Conditions:
Hepatitis B;   Liver Cancer;   Hepatitis C 
Intervention:
 
 
 

 
108
Recruiting
Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
Conditions:
Hepatocellular Carcinoma;   Hepatitis B Virus;   Recurrence 
Interventions:
Drug: antiviral treatment(lamivudine or entecavir) after the Procedure/Surgery (radical resection of HBV-related HCC);   Drug: no antiviral treatment(lamivudine or entecavir) after the Procedure/Surgery (radical resection of HBV-related HCC) 
 
 

 
109
Not yet recruiting
Efficacy of Clevudine Plus Lamivudine for Lamivudine-Resistant Chronic Hepatitis B Patients
Condition:
Chronic Hepatitis B 
Interventions:
Drug: lamivudine, adefovir;   Drug: clevudine and adefovir 
 
 

 
110
Recruiting
Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
Conditions:
Alcohol Dependence;   Chronic Hepatitis C 
Interventions:
Behavioral: Motivational Enhancement Therapy (MET);   Behavioral: Health education 
 
 

 
111
Recruiting
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
Condition:
Hepatitis C 
Interventions:
Drug: MP-424;   Drug: Ribavirin;   Drug: Peginterferon Alfa-2b;   Drug: Ribavirin;   Drug: Peginterferon Alfa-2b 
 
 

 
112
Recruiting
Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.
Condition:
Hepatitis C 
Intervention:
Procedure: fine-needle aspiration biopsy 
 
 

 
113
Recruiting
Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients
Condition:
Chronic Hepatitis C 
Interventions:
Drug: alb-interferon alfa 2b;   Drug: alb-interferon alfa 2b;   Drug: alb-interferon alfa 2b;   Drug: alb-interferon alfa 2b;   Drug: peg-interferon 
 
 

 
114
Recruiting
Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial
Condition:
Chronic Hepatitis C 
Intervention:
Drug: consensus interferon (Interferon Alfacon-1) and ribavirin 
 
 

 
115
Recruiting
Efficacy of Peginterferon Alfa-2b (SCH 54031) vs Glycyrrhizin in Interferon(IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (Study P04773)
Condition:
Hepatitis C, Chronic 
Interventions:
Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Glycyrrhizin [Monoammonium glycyrrhizinate, glycine, L-cysteine monohydrochloride] 
 
 

 
116
Recruiting
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With PegIntron (Peginterferon α-2b) and Rebetol (Ribavirin) in the Czech Republic (Study P04588)
Conditions:
Hepatitis C, Chronic;   Hepatitis C 
Interventions:
Biological: PegIntron (peginterferon alfa-2b; peginterferon α-2b; SCH 54031);   Drug: Rebetol (ribavirin; SCH 18908) 
 
 

 
117
Recruiting
Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment
Condition:
Chronic Hepatitis C 
Intervention:
Drug: Omega DUROS device 
 
 

 
118
Recruiting
Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B
Condition:
Chronic Hepatitis B 
Intervention:
Drug: Telbivudine 
 
 

 
119
Recruiting
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
Condition:
Hepatitis C, Chronic 
Intervention:
Drug: PEGylated recombinant interleukin 29 (PEG-rIL-29) 
 
 

 
120
Recruiting
 

 
121
Recruiting
High-Dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4
Condition:
Chronic Hepatitis C Genotype One or Four 
Interventions:
Drug: ribavirin;   Drug: ribavirin 
 
 

 
122
Not yet recruiting
Effects of Sho-Saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C
Condition:
Hepatitis C Virus 
Interventions:
Other: standardized herbal formula, Sho-saiko-to (SST);   Other: placebo capsule identical to the active herbal formula 
 
 

 
123
Recruiting
Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus
Condition:
Chronic Hepatitis C 
Interventions:
Drug: ANZ-521;   Drug: Placebo 
 
 

 
124
Recruiting
Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C
Condition:
Chronic Hepatitis C 
Interventions:
Dietary Supplement: Viusid;   Other: Placebo 
 
 

 
125
Recruiting
Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2
Conditions:
HIV Infections;   Hepatitis A;   Hepatitis B 
Interventions:
Biological: Twinrix;   Biological: interleukin-2 
 
 

 
126
Recruiting
Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
Condition:
Chronic Hepatitis C 
Intervention:
Biological: Albinterferon alfa 2b 
 
 

 
127
Recruiting
Effective Treatment of Hepatitis C in Substance Users
Conditions:
Hepatitis C;   Opiate Dependence 
Interventions:
Procedure: Methadone and standard HCV therapy;   Procedure: Methadone and directly observed HCV therapy;   Procedure: Buprenorphine and directly observed HCV therapy;   Procedure: Buprenorphine and standard HCV therapy 
 
 

 
128
Recruiting
Post-Marketing Surveillance of HIV-Infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
Conditions:
Chronic Hepatitis C;   Hepatitis C;   HIV Infections 
Interventions:
Biological: PegIntron (peginterferon alfa-2b; SCH 54031) pen;   Drug: Rebetol (ribavirin; SCH 18908) 
 
 

 
129
Recruiting
A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C
Condition:
Hepatitis C 
Interventions:
Drug: MP-424(H), PEG-IFN-a-2b, RBV;   Drug: MP-424 (L), PEG-IFN-a-2b, RBV 
 
 

 
130
Recruiting
Treatment of Alcohol-Related Hepatitis With Arginine
Condition:
Alcoholic Hepatitis 
Intervention:
Drug: Arginine 
 
 

 
131
Recruiting
 

 
132
Recruiting
Pioglitazone Plus Peginterferon and Ribavirin to Treat HIV 1-Infected Patients With HCV Genotype 1 Infection
Conditions:
Hepatitis C;   Insulin Resistance;   Hepatic Steatosis;   HIV Infections 
Intervention:
Drug: Pioglitazone 
 
 

 
133
Recruiting
Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV
Conditions:
Hepatitis C;   HIV Infections 
Interventions:
Drug: Efavirenz;   Drug: Emtricitabine/Tenofovir disoproxil fumarate 
 
 

 
 
135
Recruiting
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.
Conditions:
Cirrhosis;   Chronic Hepatitis C 
Intervention:
Drug: Viusid (nutritional supplement) 
 
 

 
136
Recruiting
Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin
Condition:
Chronic Hepatitis C 
Interventions:
Drug: Pegylated interferon alfa-2a and ribavirin;   Drug: Pegylated interferon alfa-2a and ribavirin;   Drug: Pegylated interferon alfa-2a and ribavirin 
 
 

 
137
Recruiting
Polymorphisms of Fibrosis-Relating Genes on Outcome of HCV-Related Chronic Liver Disease
Conditions:
Hepatitis C Virus Infection;   Chronic Liver Disease 
Interventions:
Genetic: cytokine;   Genetic: fibrosis-related cytokine gene;   Genetic: cytokine polymorphism 
 
 

 
138
Recruiting
Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-Coinfected Patients
Conditions:
Hepatitis C, Chronic;   HIV Infections 
Interventions:
Drug: Pegylated interferon alfa-2a and Ribavirin;   Drug: Pegylated interferon alfa 2a and Ribavirin 
 
 

 
139
Recruiting
Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis
Condition:
Chronic Hepatitis B 
Intervention:
Biological: DNA vaccine pCMVS2.S 
 
 

 
140
Recruiting
 

 
 
142
Recruiting
Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-Viral Treatment
Condition:
Chronic Hepatitis B 
Intervention:
Drug: Pegylated Interferon-alfa-2a 
 
 

 
143
Recruiting
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease
Conditions:
Thrombocytopenia;   Hepatitis C 
Intervention:
Drug: eltrombopag 
 
 

 
144
Recruiting
Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease
Conditions:
Thrombocytopenia;   Hepatitis C 
Intervention:
Drug: eltrombopag 
 
 

 
145
Recruiting
 

 
146
Recruiting
Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients
Condition:
HIV Infections 
Interventions:
Biological: GenHevac B Pasteur;   Biological: GenHevac B Pasteur;   Biological: GenHevac B Pasteur 
 
 

 
147
Recruiting
Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine
Condition:
Hepatitis C 
Interventions:
Drug: S-adenosyl-L-methionine;   Drug: betaine;   Drug: pegylated interferon alpha2b;   Drug: ribavirin 
 
 

 
148
Recruiting
 

 
149
Recruiting
Interferon-Gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-Responders
Conditions:
Hepatitis C;   Genotype 3;   Non-Responders;   Relapsers 
Interventions:
Drug: interferon alpha-2b, ribavirin, interferon-gamma,;   Drug: interferon alpha-2b, ribavirin, amantadine 
 
 

 
150
Recruiting
A Study of MDX-1106 to Treat Patients With Hepatitis C Infection
Condition:
Hepatitis C 
Interventions:
Drug: MDX1106-02;   Drug: Placebo 
 
 
151
Recruiting
A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM1)
Condition:
Hepatitis C, Chronic 
Interventions:
Biological: peginterferon alfa 2b;   Drug: ribavirin;   Drug: SCH 900518;   Drug: ritonavir 
 
 

 
152
Recruiting
Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis C
Condition:
Hepatitis C, Chronic 
Intervention:
 
 
 

 
153
Recruiting
Antibody Response and Immune Memory 15-18 Years After HBV Vaccination
Conditions:
Hepatitis B;   Vaccine 
Intervention:
Biological: Hepatitis B vaccine 
 
 

 
154
Recruiting
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
Condition:
Hepatitis C, Chronic 
Interventions:
Drug: peginterferon alfa-2a (40KD) [PEGASYS];   Drug: Copegus;   Drug: Pioglitazone 
 
 

 
155
Recruiting
A Randomized Trial of Vaccine Adherence in Young Injection Drug Users - 1
Conditions:
Adherence;   Community Outreach;   HIV Risk Behaviors;   Hepatitis A Vaccines;   Hepatitis B Vaccines;   Hepatitis C;   Needle-Exchange Programs;   Substance Abuse, Intravenous 
Intervention:
Behavioral: Needle-Exchange Programs 
 
 

 
156
Recruiting
Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals
Conditions:
HIV Infections;   Hepatitis C 
Interventions:
Biological: Twinrix;   Biological: Decavac 
 
 

 
157
Recruiting
Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine
Condition:
Hepatitis B, Chronic 
Interventions:
Drug: Telbivudine;   Drug: oral adefovir 
 
 

 
158
Recruiting
Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation
Conditions:
Chronic Hepatitis C;   Liver Transplantation 
Intervention:
Drug: cyclosporin 
 
 

 
159
Recruiting
Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection in Peritoneal Dialysis Patients?
Conditions:
Peritoneal Dialysis;   Renal Disease, End-Stage 
Intervention:
Biological: Engerix-B 
 
 

 
160
Recruiting
Chronic Hepatitis C and Insulin Resistance
Conditions:
Hepatitis C;   Insulin Resistance 
Intervention:
 
 
 

 
161
Not yet recruiting
Interferon-Alpha Lozenges for Prevention of Relapse in Hepatitis C
Condition:
Hepatitis C, Chronic 
Interventions:
Drug: interferon-alpha lozenges;   Drug: placebo lozenges 
 
 

 
162
Recruiting
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
Conditions:
Hepatitis C, Chronic;   Cognition Disorders;   Fatigue Syndrome, Chronic;   Major Depressive Disorder 
Intervention:
Drug: Interferon and ribavirin 
 
 

 
163
Not yet recruiting
Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients
Condition:
Chronic Hepatitis C 
Interventions:
Drug: Peginterferon alpha-2a and ribavirin;   Drug: Peginterferon alpha-2a , ribavirin and betaine 
 
 

 
164
Not yet recruiting
 

 
165
Recruiting
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA
Condition:
Hepatitis B, Chronic 
Interventions:
Drug: Entecavir;   Drug: Lamivudine 
 
 

 
166
Recruiting
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection
Condition:
Hepatitis C 
Intervention:
Procedure: Liver biopsy 
 
 

 
 
168
Recruiting
 

 
169
Not yet recruiting
 

 
 
171
Recruiting
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
Condition:
Hepatitis C, Chronic 
Interventions:
Drug: BI 201335;   Drug: Peginterferon alfa-2a (Pegasys);   Drug: Ribavirin (Copegus) 
 
 

 
172
Recruiting
A Study of Combination Treatment With PEGASYS (Peginterferon Alfa-2a (40KD) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C.
Condition:
Hepatitis C, Chronic 
Interventions:
Drug: peginterferon alfa-2a (40KD) [PEGASYS];   Drug: peginterferon alfa-2a (40KD) [PEGASYS];   Drug: ribavirin [Copegus];   Drug: ribavirin [Copegus] 
 
 

 
 
174
Recruiting
Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects
Condition:
Chronic Hepatitis C 
Intervention:
Drug: IDX184 
 
 

 
175
Recruiting
Placebo-Controlled, Dose-Escalation Study of the Safety of IMO-2125 in Hepatitis C-Infected Patients
Condition:
Hepatitis C 
Interventions:
Drug: IMO-2125;   Drug: placebo 
 
 

 
176
Recruiting
Phase II Trial of Silymarin for Non-Cirrhotic Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment
Condition:
Non Cirrhotic Chronic Hepatitis C 
Interventions:
Drug: Silymarin;   Drug: Silymarin;   Other: Placebo 
 
 

 
177
Recruiting
Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients
Condition:
Hepatitis C 
Interventions:
Drug: MK7009;   Drug: Comparator: Placebo (unspecified) 
 
 

 
178
Recruiting
A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C
Condition:
Chronic Hepatitis C 
Interventions:
Drug: Celgosivir;   Drug: Celgosivir;   Drug: Peginterferon alfa 2b + ribavirin 
 
 

 
179
Recruiting
Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
Condition:
Chronic Hepatitis C 
Intervention:
Drug: omega-3 fatty acid 
 
 

 
 
181
Recruiting
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.
Condition:
Hepatitis B, Chronic 
Intervention:
Drug: peginterferon alfa-2a (40KD) [PEGASYS] 
 
 

 
182
Not yet recruiting
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation
Conditions:
Liver Transplantation;   Hepatitis C 
Intervention:
 
 
 

 
183
Recruiting
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy
Condition:
Chronic Hepatitis C Virus Infection 
Intervention:
Other: No intervention 
 
 

 
184
Recruiting
Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections
Conditions:
HIV;   Hepatitis C;   Liver Disease;   Fatty Liver;   Steatosis 
Intervention:
Drug: Pioglitazone 
 
 

 
185
Not yet recruiting
Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B
Condition:
Hepatitis B, Chronic 
Interventions:
Drug: Lamivudine;   Drug: Telbivudine 
 
 

 
186
Recruiting
IV. Silibinin in Combination With Peg-Interferon and Ribavirin in Nonresponders
Condition:
Hepatitis C 
Intervention:
Drug: Silibinin 
 
 

 
187
Recruiting
Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection
Condition:
Hepatitis C, Chronic 
Interventions:
Drug: Ribavirin;   Drug: Peginterferon alfa 2b 
 
 

 
188
Recruiting
Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders
Condition:
Chronic Hepatitis C 
Interventions:
Drug: interferon alfa-2b;   Drug: interferon alfa-2b;   Drug: interferon alfa-2b 
 
 

 
189
Recruiting
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.
Condition:
Hepatitis C, Chronic 
Intervention:
Drug: peginterferon alfa-2a (40KD) [PEGASYS] 
 
 

 
190
Recruiting
A Multiple Ascending Dose Study of BMS-790052 in Hepatitis C Virus (HCV) Infected Subjects
Condition:
Chronic Hepatitis C 
Interventions:
Drug: BMS-790052;   Drug: Placebo 
 
 

 
191
Recruiting
Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-Resistant Chronic Hepatitis B
Condition:
Chronic Hepatitis B 
Intervention:
Drug: combination of lamivudine+adefovir vs entecavir 
 
 

 
192
Recruiting
Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM1)
Condition:
Hepatitis C, Chronic 
Interventions:
Drug: Boceprevir (SCH 503034);   Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908);   Drug: Boceprevir placebo 
 
 

 
193
Recruiting
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
Condition:
Chronic Hepatitis C 
Interventions:
Drug: MP-424;   Drug: Ribavirin;   Drug: Peginterferon Alfa-2b 
 
 

 
194
Recruiting
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
Condition:
Hepatitis B Virus 
Interventions:
Drug: Telbivudine;   Drug: Tenofovir;   Drug: Telbivudine plus tenofovir 
 
 

 
195
Recruiting
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
Condition:
Hepatitis B, Chronic 
Interventions:
Drug: peginterferon alfa-2a (40KD) [PEGASYS];   Drug: peginterferon alfa-2a (40KD) [PEGASYS];   Drug: peginterferon alfa-2a (40KD) [PEGASYS];   Drug: peginterferon alfa-2a (40KD) [PEGASYS] 
 
 

 
196
Recruiting
Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM1)
Condition:
Hepatitis C, Chronic 
Interventions:
Drug: Boceprevir (SCH 503034);   Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908);   Drug: Boceprevir placebo 
 
 

 
197
Recruiting
 

 
198
Recruiting
 

 
199
Not yet recruiting
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
Condition:
Hepatitis C, Chronic 
Interventions:
Drug: peginterferon alfa-2a (40KD) [PEGASYS];   Drug: ribavirin [Copegus] 
 
 

 
200
Recruiting
Assessment of Biomarkers for Recurrent HCV Infection Post-Liver Transplantation
Condition:
Hepatitis C Virus 
Intervention: